Column

Editor's Page

Implications of the Changing Landscape in Acute Myeloid Leukemia for Clinical Pathways

05/21/2018

Acute myelogenous leukemia (AML) is a rapid progressing malignancy of the myeloid progenitor cells, characterized by an uncontrolled proliferation of primitive blast cells replacing normal bone marrow cells. It is...

Acute...

05/21/2018

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Granularity: The Missing Link in Clinical Pathways

05/15/2018

Christine M. Wilson , MS;

Alan J. Balch , PhD, MSc;

Most clinical pathways have not been designed to incorporate the full spectrum of the patient experience, which includes elements not immediately related to clinical considerations. Changing that requires a...

Most...

05/15/2018

Journal of Clinical Pathways

Pharma Insights

Factors Influencing the Implementation of Value-Based Contracting Between Pharmaceutical Manufacturers and Payers

05/15/2018

Kyle Sarnataro , BSc;

Marylou Buyse , MD, MS;

Stephen C. Carter , BSc;

Value-based payments between payers and providers are growing steadily. Yet, despite apparently high interest, value-based contracting between payers and manufacturers appears to be growing slowly and more unevenly....

...

05/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Emerging Care Delivery Models Where Payers and Providers Become One

05/15/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The trend of reducing health care costs through global capitation and aggressive contracting from payer/provider integration has and will continue to expand in the health care market. This combination will provide a...

The...

05/15/2018

Journal of Clinical Pathways

Editor's Page

Early Learnings From Innovators in the Pursuit of Value-Based Care

05/15/2018

Winston Wong , PharmD;

Making the transition from fee-for-service reimbursement to value-based models of care and payments will be slow and difficult. As the initial concepts behind value-based reimbursement and care delivery models...

Making...

05/15/2018

Journal of Clinical Pathways

Counterpoint

Understanding Provider Perceptions Is Key to Utilization and Uptake of CAR-T Therapy

04/17/2018

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...

The...

04/17/2018

Journal of Clinical Pathways

Viewpoint

The CAR-T Breakthrough: More Than Just Another Treatment Option

04/17/2018

Winston Wong , PharmD;

The ability to rewire human immune systems to fight cancer is certainly an exciting prospect. With the first 2 chimeric antigen receptor T-cell (CAR-T) therapies approved and over 200 more in clinical trials,...

The...

04/17/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Dealing With New Formulary Types: Health System Outpatient Formularies

04/17/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Developers and utilizers of clinical pathways need to understand that formulary systems encompass more than merely a list of medications approved by a managed care organization. These stakeholders should also factor...

...

04/17/2018

Journal of Clinical Pathways

Pharma Insights

Economic Assessment of Novel Gene and Cellular Therapies: Beyond Traditional Modeling

04/17/2018

Philip L. Cyr , MPH;

Larry Blandford , PharmD;

Various forms of decision health analytic modeling have been used for the last 3 decades to assess potential health economic impact of new therapies. As initial gene and cellular therapies come to market, debate is...

...

04/17/2018

Journal of Clinical Pathways

Editor's Page

Working Together to Ensure Patient Access to Clinical Advancements

04/17/2018

Winston Wong , PharmD;

It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future. While the promise of these therapies is certainly cause for enthusiasm,...

It is...

04/17/2018

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products